Abstract: The present invention relates to a method for separating sialylated oligosaccharides from a fermentation broth in which they are produced by a genetically modified microorganism The separation comprises the steps of: i) ultrafiltration; ii) nano-filtration; iii) optionally, activated charcoal treatment; and iv) treatment with strong anion and/or cation exchange resin.

Abstract: An achemo-enzymatic synthesis of oligosaccharides of formula 1 is presented wherein R is selected from —OH, —N 3 and —OR 6 wherein R 6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally substituted by one or more methyl, 2-trimethylsilyl-ethyl, —(CH 2) n —NH 2 and —(CH 2) n —N 3 wherein integer n is to 10, preferably 2 or 3, R is selected from sialyl moiety, —SO 3 H and —CH(R)—COOH wherein R is selected from H, alkyl and benzyl, R 2 is selected from H and fucosyl, R 3 is selected from H and sialyl, R 4 is selected from H and fucosyl, provided that at least one of R 3 and R 4 is H, and A is a divalent carbohydrate linker, having important biological activities and significant commercial value for the pharmaceutical and food industry.

Abstract: Crystalline pLNnH, useful in a pharmaceutical or nutritional composition, is disclosed.

Abstract: An achemo-enzymatic synthesis of oligosaccharides of formula 1 is presented wherein R is selected from —OH, —N3 and —OR6 wherein R6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally substituted by one or more methyl, 2-trimethylsilyl-ethyl, —(CH2)n—NH2 and —(CH2)n—N3 wherein integer n is to 10, preferably 2 or 3, R is selected from sialyl moiety, —SO3H and —CH(R)—COOH wherein R is selected from H, alkyl and benzyl, R2 is selected from H and fucosyl, R3 is selected from H and sialyl, R4 is selected from H and fucosyl, provided that at least one of R3 and R4 is H, and A is a divalent carbohydrate linker, having important biological activities and significant commercial value for the pharmaceutical and food industry.

Abstract: A method to form a mixture containing at least one of 2?-FL (2?-O-fucosyllactose, Fuc(?1-2)Gal(?1-4)Glc) and 3-FL (3-O-fucosyllactose, Gal(?1-4)[Fuc(?1-3)]Glc) characterized in that DFL (difucosyl-lactose, Fuc(?1-2)Gal(?1-4)[Fuc(?1-3)]Glc) is subjected to partial hydrolysis, e.g. enzymatic hydrolysis or acid hydrolysis.

Abstract: A method that can be used to make a precursor of L-fucose from D-glucose that includes the steps of a) making a compound of formula (1) from D-glucose, formula (1) wherein R1 is acyloxy, and Q is a group (a), (b), (c) or (d), formula (a), (b), (c) or (d) or wherein R1 is OH, and Q is a group (e), (f) or (g); formula (e), (f) or (g) wherein R2 is acyloxy and R3 is a sulphonyl leaving group; and b) producing 6-deoxy-L-talose from the compound of formula (1) formed in step a), wherein the moiety is a highly lipophilic protecting group; compounds according to formula (1), and use of a compound according to formula (1) are provided.

Abstract: The invention relates to a method for making precursors of HMO core structures comprising a step of reacting an N-acetyllactosamine or lacto-N-biose derivative donor with a lactose or N-acetyllactosamine derivative acceptor, wherein the donor is an oxazoline donor.

Abstract: A process for converting D-glucose into L-fucose, where a first aspect of the disclosure relates to a method of making a compound of formula (1) wherein R is independently H, alkyl or phenyl or, preferably, wherein the two germinal R groups together with the carbon atom to which they are attached form a C3-s cycloalkylidene group, including the step of treating a compound of formula (2) wherein R is defined above and R1 is a sulphonate leaving group, with a reducing complex metal hydride and, preferably, a base to form the compound of formula (1); a compound of formula (13).

Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.

Abstract: Isoquinolone derivatives of the general formula Ik? are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.

Abstract: Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.

Abstract: Isoquinolone derivatives of the general formula (I) are NK3 antagonists.

Abstract: The present invention relates to pyridine derivatives of the general formula (I) and their use as openers of the KCNQ family potassium ion channels for the treatment of CNS disorders.

Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.

Abstract: The present invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.

Abstract: Isoquinolone derivatives of the general formula are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.

Abstract: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

Abstract: Isoquinolone derivatives of the general formula (I) are NK3 antagonists.

Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.